Omega 3 Prescription Drugs Market Summary

The global omega 3 prescription drugs market size was estimated at USD 1.35 billion in 2024 and is projected to reach USD 1.80 billion by 2030, growing at a CAGR of 4.90% from 2025 to 2030. The market continues to expand steadily due to rising cases of cardiovascular diseases and the increasing use of omega 3 prescription formulations to manage hypertriglyceridemia. As healthcare professionals emphasize early prevention and targeted treatment, these drugs are becoming a critical part of lipid management therapies, strengthening their global demand.

Expanding aging populations and the growing prevalence of chronic conditions such as heart disease, diabetes, and metabolic disorders are driving higher utilization rates. As elderly individuals often require long-term treatment and monitoring, prescription omega 3 products play a significant role in maintaining cardiovascular health. Additionally, ongoing research exploring the benefits of omega 3 in neurological, inflammatory, and other emerging therapeutic areas is creating opportunities for broader product adoption in the coming years.

These market drivers, supported by strong physician recommendations, proven clinical efficacy, and insurance reimbursement policies, contribute to stable revenue generation across major markets. The presence of established pharmaceutical companies and expanding patient awareness further reinforce growth prospects.

Key Market Trends & Insights

• The North America region dominated the global omega 3 prescription drugs market with a substantial share of 42.9% in 2024, reflecting the region’s strong healthcare infrastructure, high awareness levels regarding cardiovascular health, and widespread availability of prescription-based lipid management therapies.
• The U.S. omega 3 prescription drugs market held a significant share within North America, supported by a large patient population, higher diagnosis rates of hypertriglyceridemia, and favorable reimbursement policies that encourage the use of prescription omega 3 products as part of preventive and therapeutic care.
• Based on drug, the others segment dominated the market and accounted for the largest revenue share of 48.0% in 2024. This category includes newer and advanced formulations that continue to gain acceptance due to their improved clinical efficacy and broader therapeutic applications.
• Based on application, the cardiovascular segment dominated the market and accounted for the largest revenue share of 86.8% in 2024, highlighting the extensive use of omega 3 prescription drugs in managing cardiovascular risks, lowering triglyceride levels, and supporting long-term heart health.
• Based on distribution channel, the retail pharmacy segment dominated the market and accounted for the largest revenue share of 53.6% in 2024, as patients increasingly rely on retail outlets for convenient access to prescription medications, pharmacist guidance, and routine refills.

Order a free sample PDF of the Omega 3 Prescription Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 1.35 Billion
• 2030 Projected Market Size: USD 1.80 Billion
• CAGR (2025-2030): 4.90%
• North America: Largest market in 2024

Key Companies & Market Share Insights

Key players in the global market include Amarin Pharmaceuticals Ireland Limited, Woodward Pharma Services LLC, Mankind Pharma, GLW Pharma GMBH, CSPC Pharmaceutical Group Limited, and Sofgen. These companies are major contributors to the market, focusing on developing Omega-3-based products aimed at improving cardiovascular health. Their strategic partnerships, continuous research, and investment in innovative formulations play a vital role in driving market growth. In addition, these companies are working to expand their global reach and enhance product accessibility, positioning themselves as key players in the evolving market.

Key Players

• Amarin Pharmaceuticals Ireland Limited
• Woodward Pharma Services LLC
• Mankind Pharma
• GLW Pharma GMBH
• CSPC Pharmaceutical Group Limited
• Sofgen
• WILSHIRE PHARMACEUTICALS, INC.
• Sun Pharmaceutical Industries Ltd.
• PuraCap Pharmaceutical LLC
• ChartwellPharma
• Amneal Pharmaceuticals LLC

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The omega 3 prescription drugs market is expected to witness steady expansion as cardiovascular diseases continue to affect millions globally, strengthening the need for effective triglyceride-lowering therapies. Growing awareness of the clinical benefits of omega 3 formulations, supported by physician recommendations and favorable insurance coverage, ensures consistent product adoption. The aging population and rising chronic disease burden further contribute to demand, while ongoing research into broader therapeutic applications enhances long-term potential. With North America leading the market and emerging opportunities in global regions, omega 3 prescription therapies will remain an important component of cardiovascular and metabolic health management.